Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
|Articles|December 5, 2012
Regulatory Roundup, Week of Dec. 3, 2012
Author(s)Pharmaceutical Technology Editors
FDA releases guidance documents on PET drugs, labeling of OTC sunscreen, and the use of certain phthalates as excipients.
Advertisement
The International Conference on Harmonization (ICH) has
FDA has released the following guidance documents:
Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs, Guidance , Center for Drug Evaluation and Research (CDER), December 2012. The guidance summarizes the investigational new drug application process for unapproved PET drugs.
FDA Oversight of PET Drug Products, Questions and Answers , CDER, December 2012. The guidance is intended to help producers of PET drugs meet FDA requirements for drug approval processes.
Guidance for Industry, Labeling and Effectiveness Testing: Sunscreen Drug Products for Over-the-Counter Human Use—Small Entity Compliance Guide , CDER, December 2012. This guidance is intended to help small businesses understand and comply with FDA’s labeling and testing regulations of OTC sunscreen drug products.
Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products , CDER, December 2012. This guidance provides CDER’s current thinking on the potential human health risks associated with exposure to dibutyl phthalate and di (2-ethylhexyl) phthalate.
Advertisement
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement